Academic Commons

Theses Doctoral

Integrating Functional Genomics with Systems Biology to Discover Drivers and Therapeutic Targets of Human Malignancies

Yu, Jiyang

Genome-wide RNAi screening has emerged as a powerful tool for loss-of-function studies that may lead to therapeutic target discovery for human malignancies in the era of personalized medicine. However, due to high false-positive and false-negative rates arising from noise of high-throughput measurements and off-target effects, powerful computational tools and additional knowledge are much needed to analyze and complement it. Availability of high-throughput genomic data including gene expression profiles, copy number variations from large-sampled primary patients and cell lines allows us to tackle underlying drivers causally associated with tumorigenesis or drug-resistance. In my dissertation, I have developed a framework to integrate functional RNAi screens with systems biology of cancer genomics to tailor potential therapeutics for reversal of drug-resistance or treatment of aggressive tumors. I developed a series of algorithms and tools to deconvolute, QC and post-analyze high-throughput shRNA screening data by next-generation sequencing technology (shSeq), particularly a novel Bayesian hierarchical modeling approach to integrate multiple shRNAs targeting the same gene, which outperforms existing methods. In parallel, I developed a systems biology algorithm, NetBID2, to infer disease drivers from high-throughput genomic data by reverse-engineering network and Bayesian inference, which is able to detect hidden drivers that traditional methods fail to find. Integrating NetBID2 with functional RNAi screens, I have identified known and novel driver-type therapeutic targets in various disease contexts. For example, I discovered that AKT1 is a driver for glucocorticoid (GC) resistance, a problem in the treatment of T-ALL. The inhibition of AKT1 was validated to reverse GC-resistance. Additionally, upon silencing predicted master regulators of GC resistance with shRNA screens, 13 out of 16 were validated to significantly overcome resistance. In breast cancer, I discovered that STAT3 is required for transformation of HER2+ breast cancer, an aggressive breast tumor subtype. The suppression of STAT3 was confirmed in vitro and in vivo to be an effective therapy for HER2+ breast cancer. Moreover, my analysis revealed that STAT3 silencing only works in ER- cases. Using my framework, I have also identified potential therapeutic targets for ABC or GCB-type DLBCL and subtype-based breast cancer that are currently being validated.

Files

  • thumnail for Yu_columbia_0054D_10993.pdf Yu_columbia_0054D_10993.pdf application/x-pdf 25.7 MB Download File

More About This Work

Academic Units
Biomedical Informatics
Thesis Advisors
Califano, Andrea
Degree
Ph.D., Columbia University
Published Here
October 11, 2012
Academic Commons provides global access to research and scholarship produced at Columbia University, Barnard College, Teachers College, Union Theological Seminary and Jewish Theological Seminary. Academic Commons is managed by the Columbia University Libraries.